Loading…

RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2021-06, Vol.39 (S2)
Main Authors:	Vassilakopoulos, T., Ferhanoglu, B., Horowitz, N., Mellios, Z., Kaynar, L., Zektser, M., Symeonidis, A., Piperidou, A., Kalpadakis, C., Akay, O. M., Atalar, A. C., Katodritou, E., Leonidopoulou, T., Papageorgiou, S., Tadmor, T., Gutwein, O., Karakatsanis, S., Ganzel, C., Karianakis, G., Isenberg, G., Gainaru, G., Vrakidou, E., Palassopoulou, M., Ozgur, M., Siakantaris, M., Paydas, S., Tsirigotis, P., Tsirogianni, M., Hatzimichael, E., Tuglular, T., Chatzidimitriou, C., Megalakaki, E., Kanellias, N., Zikos, P., Koumarianou, A., Gafter‐Gvili, A., Angelopoulou, M., Karmiris, T., Gurion, R.
Format:	Article
Language:	English
Subjects:	B-cell lymphoma Immunotherapy Lymphoma Monoclonal antibodies Rituximab Targeted cancer therapy
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!